Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : BMKS More internet acquisitions in 2000 -- Ignore unavailable to you. Want to Upgrade?

To: Ken O'Connor who wrote (914)	12/28/2001 3:25:17 PM
From: jmhollen	Read Replies (1) \| Respond to of 1453

O/T: Only reason I brought it up was your subject tweaked my memory. Here's an "..FYI.." on that other company I was thinking of: Synthetic Blood International Announces Results of Animal Stroke Studies COSTA MESA, Calif., Nov 13, 2001 (BW HealthWire) -- Synthetic Blood International Inc. (OTCBB: SYBD) announced today that results from a series of experiments in rats suggest that Oxycyte(TM), SYBD's perfluorocarbon (PFC) based blood substitute and therapeutic oxygen carrier, may be effective in treating strokes. The studies were performed by a research group in the Mannheim Neurosurgical Research Laboratory at the University of Heidelberg in Germany. The experiments, which were done in a middle cerebral artery occlusion model using rats, consistently showed a significant decrease in necrotic lesion volume or damage to the brain in Oxycyte-treated animals compared to control animals. The MCA occlusion was left in place for eight hours in order to mimic the clinical situation where there might be a significant delay before a stroke victim might receive successful clot lysis and initiation of reperfusion. Animals breathing 100% oxygen were given a systemic intravenous infusion of 60% Oxycyte or a saline control infusion. In addition to decreasing the volume of brain tissue damage induced by MCA occlusion, significantly elevated oxygen levels in the brain were found in Oxycyte-treated animals compared to control animals. The Heidelberg group and SYBD are continuing to collaborate on optimizing the Oxycyte formula and method of delivery for this indication. "Although further studies in animals and humans need to be done to confirm these findings, we are delighted with these early results that appear to support Oxycyte's utility as a therapeutic oxygen carrier," said Robert Nicora, SYBD president. "Even more exciting is the therapeutic response to systemic IV infusion which suggests that Oxycyte may be used as a first line therapy for stroke victims in the field before they arrive at the hospital." "We hope that Oxycyte may delay the onset of stroke-induced tissue damage," said Dr. Johannes Woitzik, lead investigator for the Heidelberg research group. "Other therapeutic treatment concepts, which typically are only beneficial if initiated shortly after stroke onset, could be performed even if the patient reaches the clinic temporally delayed." SYBD is developing Oxycyte as a blood substitute in surgery and trauma, and as a possible therapeutic oxygen treatment for stroke, heart attacks, malignant tumors, organ preservation for transplantation and ulcers. The company is also developing Fluorovent(TM), a perfluorocarbon-based liquid breathing product for patients with respiratory distress on a ventilator, and an implanted biosensor system for continuous glucose monitoring in diabetics. The company is traded under the symbol SYBD on the OTC Electronic Bulletin Board. The company's Web site is sybd.com and e-mail address is info@sybd.com. CONTACT: Synthetic Blood International Inc., Costa Mesa Joan Mahan, 800/809-6054